Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

WCG

- PMLiVE

Roche/Jazz share positive phase 3 results for lung cancer combination therapy

Approximately 30,000 new cases of small cell lung cancer are reported in the US every year

- PMLiVE

Roche shares positive 96-week results for multiple sclerosis candidate fenebrutinib

The immune-mediated disease affects more than 2.9 million people worldwide

- PMLiVE

Roche’s Perjeta-based breast cancer regimen shows sustained survival benefits

Approximately 56,800 new breast cancer cases are diagnosed in the UK every year

- PMLiVE

AXON NAMES NEW PRESIDENT AND MANAGING PARTNER, TINA HAHN, AS RALPH SUTTON CHANGES LANE

April 30, 2025—Tina Hahn, who joined AXON in 2012 as Vice President, will now take on the role of AXON’s President and Managing Partner.

AXON

- PMLiVE

Roche to boost US footprint with $50bn investment over next five years

The commitment is aimed at bolstering the company’s pharmaceutical and diagnostics divisions

- PMLiVE

Roche’s Genentech enters $765m autoimmune disease partnership with Repertoire

The collaboration will leverage Repertoire’s immune mapping DECODE platform

- PMLiVE

Roche’s Columvi granted EC approval to treat diffuse large B-cell lymphoma

Approximately 38,000 people are diagnosed with DLBCL every year in Europe

- PMLiVE

Roche and Oxford BioTherapeutics enter oncology partnership worth over $1bn

The companies will aim to discover new antibody-based therapeutics for cancer

- PMLiVE

Roche to launch new innovation centre at Harvard’s Enterprise Research Campus

The first phase of construction on the ERC is expected to be complete in 2026

- PMLiVE

Roche and Zealand partner on mid-stage obesity candidate in deal worth $5.3bn

The companies will develop petrelintide as both a standalone therapy and in combination with Roche’s CT-388

- PMLiVE

Roche’s Genentech granted FDA approval for TNKase in acute ischaemic stroke

TNKase is the first stroke medicine to be approved by the regulator in almost three decades

- PMLiVE

Roche’s Evrysdi tablet formulation granted FDA approval for spinal muscular atrophy

The progressive neuromuscular disease affects approximately one in every 10,000 babies globally

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links